Literature DB >> 6376799

A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis.

J Dequeker, P Van Wanghe, W Verdickt.   

Abstract

One hundred sixty-two consecutive patients with rheumatoid arthritis (RA) were studied for possible association between HLA antigens, particularly DR antigens, and disease characteristics and adverse reactions to gold or D-penicillamine treatment. The frequency of HLA-DR4 was significantly increased: 62% in RA compared to 23% in controls. An association of HLA-DR4 with a positive family history for RA was also found. HLA-DR4 was not associated with subcutaneous nodules or keratoconjunctivitis, presence of rheumatoid factor, or ANA positivity. No increased prevalence of HLA-DR3 was found in patients who developed drug related toxicity (e.g., proteinuria for gold or D-penicillamine). Of the 27 patients in whom proteinuria developed, only 5 were DR3 positive. A significant association with D-penicillamine induced proteinuria and HLA-B8 gene was found. Our results obtained in a systematic survey do not confirm previous reports of a significant association between HLA-DR3 and drug toxicity, but confirm the association between HLA-DR4 and the development of RA and HLA-B8 and D-penicillamine induced proteinuria.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376799

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

2.  HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin.

Authors:  M Kurosaki; H Takagi; M Mori
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

3.  Association of HLA-B35 with mucocutaneous lesions in Israeli patients with rheumatoid arthritis receiving gold treatment.

Authors:  M Tishler; D Caspi; E Gazit; M Yaron
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

4.  HLA-DR antigens in rheumatoid arthritis. A Swiss collaborative study; final report. Swiss Federal Commission for the Rheumatic Diseases, Subcommission for Research.

Authors: 
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

5.  Remarkably similar response to gold therapy in HLA identical sibs with rheumatoid arthritis.

Authors:  L B van de Putte; F Speerstra; P L van Riel; A M Boerbooms; P J van't Pad Bosch; P Reekers
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

6.  Penicillamine nephropathy.

Authors:  C L Hall
Journal:  BMJ       Date:  1988-07-09

7.  Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis with gold induced thrombocytopenia or proteinuria.

Authors:  D P Singal; B Reid; D Green; M D'Souza; W G Bensen; W W Buchanan
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

8.  Gold induced nephropathy in rheumatoid arthritis and HLA class II genes.

Authors:  L I Sakkas; I C Chikanza; R W Vaughan; K I Welsh; G S Panayi
Journal:  Ann Rheum Dis       Date:  1993-04       Impact factor: 19.103

Review 9.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

10.  HLA-D region genes and rheumatoid arthritis (RA): importance of DR and DQ genes in conferring susceptibility to RA.

Authors:  D P Singal; D Green; B Reid; D D Gladman; W W Buchanan
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.